AUTHORS
Nisha Joseph, MD, Maximilian Merz, MD2, Uma Chandrasekaran, PhD3, Riadh Lobbardi, PhD4, Eunju Hurh, PhD5, Anne Keating, PharmD6, Laura Versmee, MD7, Andrew Sochacki, MD8
AFFILIATIONS
1 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 C4 Therapeutics, Watertown, Massachusetts, United States
4 C4 Therapeutics, Watertown, Massachusetts, United States
5 C4 Therapeutics, Watertown, Massachusetts, United States
6 C4 Therapeutics, Watertown, Massachusetts, United States
7 C4 Therapeutics, Watertown, Massachusetts, United States
8 South Texas Accelerated Research Therapeutics (start) Midwest, Grand Rapids, United States
ABSTRACT
Background: IKZF1 and IKZF3 are key transcription factors for myeloma cell survival due to the activation of IRF4. Additionally, MM progression is supported by an active immunosuppressive microenvironment including dysfunctional and exhausted T-cells. Cemsidomide is a novel, highly potent, cereblon-based, IKZF1/3 MonoDAC® degrader, with a similar mechanism of action as BMS’s IMiD® or CELMoD® degraders for MM. Data from an ongoing Phase 1 trial of cemsidomide shows compelling anti-myeloma activity, differentiated safety and tolerability profile and immunomodulatory effects across all dose levels (IMS 2025 & EHA 2026). Elranatamab (ELRA) is a humanized bispecific antibody that simultaneously binds to BCMA, which is highly expressed on myeloma cells, and CD3 on CD8+ T-cells. Single-agent ELRA induced deep and durable responses with a manageable safety profile in pts with RRMM enrolled in the MagnetisMM-3 trial. The combination of cemsidomide and elranatamab leverages their distinct but complementary anti-myeloma mechanisms to potentiate a multi-pronged attack on MM cells. This strategy helps overcome the immunosuppressive tumor microenvironment via decreased T-cell exhaustion as well as T-cell activation that may combat drug resistance, ultimately improving the depth and durability of response in pts with RRMM.
Methods: This Phase 1b study is designed to evaluate the safety, tolerability, PK/PD and anti-myeloma activity of cemsidomide in combination with ELRA. Approximately 54 subjects will be enrolled at different dose levels of cemsidomide, starting at 75 µg, in combination with ELRA. To further explore safety and antimyeloma activity, select dose levels may be expanded. Bayesian optimal interval design (BOIN) will be employed. Eligibility criteria include a documented diagnosis of MM with measurable disease per IMWG criteria, ECOG ≤ 2, and adequate organ function. Patients in escalation must have received 2-4 prior lines of therapy while patients in expansion cohorts must receive 1-3 prior lines of therapy. All patients must have received a prior IKZF 1/3 degrader other than cemsidomide and cannot have received a prior BCMA- directed TCE or CAR-T therapy. Elranatamab will be administered SC starting with step-up dosing followed by biweekly dosing. Cemsidomide will be taken by mouth for 14 days on/14 days off after step-up dosing of elranatamab (1 cycle=28 days). Dexamethasone will be administered weekly for the first 4 cycles or until a response, whichever occurs first. Study treatment will continue until PD, intolerable toxicity or pt withdraws consent. Key objectives include establishing safety of the combination based on incidence of DLTs and SAEs/AEs, evaluating the PK of cemsidomide and elranatamab and assessing the antimyeloma activity per IMWG criteria. A safety review committee will be overseeing the study. The study was open for enrollment as of February 2026 and the first patient was dosed in March 2026, NCT07280013.
DISCLOSURES
Nisha Joseph, MD: Janssen - Honoraria; Legend - Honoraria; BMS - Honoraria; Regeneron - Research Funding; Janssen - Research Funding; BMS - Research Funding; Novartis - Research Funding; BMS - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony)